To extend these approaches to pediatric leukemias, we profile samples from patients diagnosed with one of two well-defined subtypes: BCR::ABL1-like and ETV6::RUNX1 B-ALL, which have distinct prognoses, known signaling pathways, and treatment approaches. Here, RUNX1 is linked to leukemia.